FDA Orange Book
Is there a generic for Lisraya?
Lisraya contains brepocitinib. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Lisraya (brepocitinib). The Orange Book shows its last listed patent expires August 19, 2035 and its last listed exclusivity ends August 27, 2031.
Run it in Rivvi
Map Lisraya and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Lisraya products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | EQ 30MG BASE | Marketed (Rx) | None | 0 | None |
NDA 220106, held by PRIOVANT THERAPEUTICS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Lisraya patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 9663526 | August 19, 2035 | Drug substance, Drug product | None | 220106 |
| 11197867 | August 19, 2035 | Drug substance, Drug product | None | 220106 |
Lisraya exclusivity
| Code | Meaning | Expires | NDA |
|---|---|---|---|
| NCE | New chemical entity | August 27, 2031 | 220106 |
Lisraya NDC codes
Questions
Is there a generic for Lisraya?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Lisraya (brepocitinib). The Orange Book shows its last listed patent expires August 19, 2035 and its last listed exclusivity ends August 27, 2031.
What is the generic name for Lisraya?
The active ingredient in Lisraya is brepocitinib, per the FDA Orange Book.
When does the Lisraya patent expire?
The last patent listed for Lisraya in the Orange Book expires August 19, 2035. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.